
In this video soundbite from the ERS-ISIAN 2025 symposium, Dr. Sietze Reitsma discusses about indirect comparison of biologics for CRSwNP, focusing on clinical outcomes like symptom relief and safety and also highlights dupilumab, omalizumab, and mepolizumab as effective and well-tolerated options.

Prof. Salvatore Oliva and Dr. Milli Gupta discuss the importance of long-term care, multidimensional assessment, and the latest data for biologics.

In this video soundbite from the EAACI 2025 symposium, Dr. Philippe Gevaert explains how biologic options for uncontrolled CRSwNP are increasing, and phase 3 studies of approved biologics show improved outcomes and decreased SCS use/surgery in patients with CRSwNP. Additionally, he explains how biologics targeting type 2 inflammatory pathophysiology potentially improve outcomes for eligible patients with co-existing CRSwNP and asthma.
Join Sanofi and Regeneron for an educational symposium on type 2 inflammation, patient characteristics predictive of disease recurrence, and emerging real-world evidence for biologics in CRSwNP.

In this video soundbite from the ERS-ISIAN 2025 symposium, Dr. Sietze Reitsma discusses findings from the EVEREST trial, the first head-to-head study comparison of dupilumab and omalizumab in patients with severe CRSwNP and coexisting asthma. It also introduces the ongoing TORNADO study.
Join Sanofi and Regeneron for an educational symposium on type 2 inflammation, patient characteristics predictive of disease recurrence, and emerging real-world evidence for biologics in CRSwNP.

Explore the dynamic advancements in COPD biologic therapies. Prof. Klaus Rabe, MD, Prof. Claus Vogelmeier, MD, and Prof. Wisia Wedzicha, MD, present and analyze the latest clinical data, offering key insights into current and emerging therapeutic strategies for managing COPD.

Join Profs. Sachio Takeno and Joaquim Mullol for an educational symposium highlighting the multifaceted burden associated with loss of smell and congestion in patients with uncontrolled CRSwNP.
Dr Gutiérrez Junquera discusses ESPGHAN guidelines, clinical data, and long-term management strategies for pediatric EoE.
Prof. Greuter presents clinical data for approved treatments for adult EoE.

In this educational presentation, Profs. Vibeke Backer and Sietze Reitsma cover key aspects of type 2 inflammation and its role in the pathogenesis and management of CRSwNP and practical strategies for optimizing disease control and improving patient outcomes.
Profs. Greuter, Savarino, and Giordano discuss multidimensional EoE assessment, tailoring long-term care to patient needs, and recent clinical data.